ORPHA:980
Absence of the pulmonary artery
Also known as: Aplasia of pulmonary artery · UAPA · Unilateral Pulmonary Artery Absence · Unilateral pulmonary artery agenesis
Publications
883
81th percentile
Trials
0
Interventional, condition-specific
Researchers
889
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare vascular anomaly characterized by absence of the right or left pulmonary artery, usually ending within 2 cm of its expected origin from the pulmonary trunk. Patients often also have other cardiovascular abnormalities and respective symptoms and are then typically diagnosed in infancy or childhood, while isolated cases generally present with a mild clinical course and may go undiagnosed until adulthood. Presenting clinical features in isolated cases include hemoptysis, exertional dyspnea, and recurrent respiratory infections. The condition is typically accompanied by marked changes of lung tissue and may, if unrecognized, result in massive hemoptysis and pulmonary hypertension.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0020007
- UMLS:C0265905
Additional Mondo synonyms (6)
agenesis of pulmonary artery · aplasia of pulmonary artery · pulmonary artery absent · pulmonary artery agenesis · unilateral pulmonary artery absence · unilateral pulmonary artery agenesis
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
883 matched papers (406 in last 10 years) Source
- Phenotype characterisedPresent
37 HPO annotations (e.g. Pulmonary arterial hypertension; Exercise intolerance; Recurrent pneumonia) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
37
Associated phenotypes · MONDO:0020007
- Pulmonary arterial hypertension
- Exercise intolerance
- Recurrent pneumonia
- Patent ductus arteriosus
- Bronchiectasis
Showing 5 of 37 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
883
883 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
883 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
406 in the last 10 years · medium confidence · 81th percentile (publications denominator)
Phrase hits: 883 · MeSH hits: 0
Who's working on it?
889
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Kumar S4 papers · 2023
Department of Cardiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India. sudeep@sgpgi.ac.in
Papers in Europe PMC - 02Gangopadhyay D2 papers · 2025
Department of Pediatric Cardiology, Rabindranath Tagore International Institute of Cardiac Sciences, Kolkata, West Bengal, India.
Papers in Europe PMC - 03Kobayashi K2 papers · 2025
Department of Cardiac Surgery, Daiyukai General Hospital, Ichinomiya, Aichi, Japan.
Papers in Europe PMC - 04
- 05Miyoshi K2 papers · 2026
Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama, Japan.
Papers in Europe PMC - 06Okazaki M2 papers · 2026
Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama, Japan.
Papers in Europe PMC - 07Raymond A2 papers · 2018
Paediatrics & Neonatology Unit, "Guglielmo da Saliceto" City Hospital, Cantone del Cristo, 50, 29121, Piacenza, Italy.
Papers in Europe PMC - 08Redmond KC2 papers · 2017
Professor Eoin O'Malley National Cardiothoracic & Transplant Unit, Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland.
Papers in Europe PMC - 09Roy M2 papers · 2025
Department of Pediatric Cardiology, Rabindranath Tagore International Institute of Cardiac Sciences, Kolkata, West Bengal, India.
Papers in Europe PMC - 10Saedi S2 papers · 2024
Rajaie Cardiovascular Medical and Research Center Iran University of Medical Sciences Tehran Iran.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
medium confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 38 · after dedupe 38 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 38 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (38)
- isrctn·ISRCTN16931476·Recruiting·Pre-eclampsia prevention by timed birth at term 2 (PREVENT-2): a randomised trial
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN61928422·Recruiting·A non-interventional study analyzing the characteristics of patients hospitalized in France for acute exacerbations of COPD and the factors predicting disease progression
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN26150156·Recruiting·A trial of indocyanine green and near-infrared fluorescence in paediatric oncology surgery
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14164179·Stopped·A study to test the safety and effectiveness of using mutant pro-urokinase and low-dose alteplase to unblock blood vessels in heart attack patients before receiving treatment at a hospital with PCI capability
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN23584582·No longer recruiting·Platform study Kalidescope: A Phase 1/2 Open-label Platform Study to Evaluate the Safety and Efficacy of Multiple Amivantamab-based Therapeutic Combinations in Participants with Advanced,
Unresectable Lung Cancer (LC)
ISA1 METalmark (now closed in UK): A phase I/II open-label platform study to evaluate the safety and efficacy of multiple amivantamab-based therapeutic combinations in participants with advanced, unresectable lung cancer
ISA2 Polydamas: A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Cetrelimab Combination Therapy in Metastatic Non-small Cell Lung Cancer
ISA3 SwalloWTail: A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxel Combination Therapy in Metastatic Non-small Cell Lung Cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17794752·No longer recruiting·Can the use of a VasQ external support device improve the maturation and utilization of wrist distal arteriovenous fistulas?
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14411820·Recruiting·Long-term outcomes of early stent thrombosis after implanting new-generation drug-eluting stents
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN83474167·No longer recruiting·Phase II open-label trial of atezolizumab in patients with urinary tract squamous cell carcinoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN41632964·No longer recruiting·Preeclampsia prevention by timed birth at term
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN79552451·No longer recruiting·Phase I study to evaluate the safety of mRNA-0184 in participants with heart failure
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN37043682·No longer recruiting·A study in healthy males to assess how the radiolabelled test medicine RO7223280 is broken down, processed and removed from the body
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN60385283·No longer recruiting·A study to investigate the safety, tolerability, and potential effect of RXC007 in patients with idiopathic pulmonary fibrosis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN22121045·No longer recruiting·Catheter-directed thrombolysis in patients with acute pulmonary embolism
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN41969875·No longer recruiting·A study to investigate the processing by the body, safety, and side effects of gantenerumab in healthy Chinese participants following a single dose
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16766375·No longer recruiting·Evaluation of a new 3D cardiac MRI sequence for the identification of myocardial scars and fibrosis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN18275480·Recruiting·Heart failure in patients with advanced chronic kidney disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11503604·Recruiting·A Phase II clinical trial to compare the effectiveness of gemcitabine and nab-paclitaxel administered in combination with ATRA vs without ATRA in patients with locally advanced treatment-naïve pancreatic cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11713182·No longer recruiting·Testing the effectiveness of almitrine bismesylate in the treatment of COVID-19
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN92249277·No longer recruiting·New biomarkers of endothelial dysfunction
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN62396133·No longer recruiting·World maternal antifibrinolytic trial-2
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN96273644·No longer recruiting·A study to see how effective the drug Axitinib is at preventing cancer cells from growing and to see if this means that patients with kidney cancer require less extensive surgery
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13930454·No longer recruiting·Minimally invasive thoracoscopically-guided right minithoracotomy versus conventional sternotomy for mitral valve repair
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN31681480·No longer recruiting·The effect of air or enriched air nitrox breathing during simulated diving on intravascular bubble formation following decompression
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN19023197·No longer recruiting·The effects of fluid loading on cardiac response and acid-base status in the critically ill
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN32238279·No longer recruiting·Can electrically-assisted bicycles be recommended for patients with heart disease?
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Absence of the pulmonary artery — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Absence of the pulmonary artery" OR "Absence of pulmonary artery" OR "Aplasia of pulmonary artery" OR "Aplasia of the pulmonary artery" OR "Unilateral Pulmonary Artery Absence" OR "Unilateral pulmonary artery agenesis" OR "agenesis of pulmonary artery" OR "agenesis of the pulmonary artery" OR "pulmonary artery absent" OR "pulmonary artery agenesis"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Absence of the pulmonary artery" OR "Absence of pulmonary artery" OR "Aplasia of pulmonary artery" OR "Aplasia of the pulmonary artery" OR "Unilateral Pulmonary Artery Absence" OR "Unilateral pulmonary artery agenesis" OR "agenesis of pulmonary artery" OR "agenesis of the pulmonary artery" OR "pulmonary artery absent" OR "pulmonary artery agenesis"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: UAPA
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T16:05:34.934Z
